Tvardi Therapeutics (NASDAQ:TVRD) Posts Earnings Results

Tvardi Therapeutics (NASDAQ:TVRD) released its quarterly earnings results on Tuesday. The company reported ($0.78) earnings per share (EPS) for the quarter, FiscalAI reports.

Tvardi Therapeutics Stock Down 0.6%

TVRD stock opened at $3.18 on Wednesday. Tvardi Therapeutics has a twelve month low of $3.05 and a twelve month high of $43.65. The company has a market cap of $29.83 million, a PE ratio of -0.33 and a beta of 0.14. The business’s 50-day simple moving average is $3.81 and its 200 day simple moving average is $9.00.

Analyst Upgrades and Downgrades

TVRD has been the subject of several analyst reports. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Finally, Wall Street Zen raised shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.50.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Tvardi Therapeutics in the second quarter worth $43,000. Headlands Technologies LLC acquired a new stake in Tvardi Therapeutics during the second quarter worth $80,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics during the second quarter worth $92,000. Finally, Squarepoint Ops LLC bought a new stake in Tvardi Therapeutics in the 3rd quarter valued at $318,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.